Cover Image
市場調查報告書

Stemedica Cell Technologies, Inc.的產品平台分析

Stemedica Cell Technologies, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 293929
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
Stemedica Cell Technologies, Inc.的產品平台分析 Stemedica Cell Technologies, Inc. - Product Pipeline Review - 2015
出版日期: 2015年06月24日 內容資訊: 英文 27 Pages
簡介

Stemedica Cell Technologies, Inc是利用幹細胞技術進行醫藥品的開發及製造的生物醫藥品企業。

本報告提供Stemedica Cell Technologies, Inc.的產品開發平台現狀及各開發階段比較分析,提供您藥物簡介,開發平台分析與最新趨勢,現在暫停中的計劃等資訊。

Stemedica Cell Technologies, Inc.的基本資料

Stemedica Cell Technologies, Inc.概要

  • 主要資訊
  • 企業資料

Stemedica Cell Technologies, Inc.:R&D概要

  • 主要的治療範圍

Stemedica Cell Technologies, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Stemedica Cell Technologies, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
  • 臨床實驗許可申請 (IND)/臨床研究授權 (CTA) 階段的產品/聯合治療模式
    • 前臨床階段的產品/聯合治療模式

Stemedica Cell Technologies, Inc.:藥物簡介

  • 間質幹細胞
  • 神經幹細胞
  • 視網膜表皮細胞
  • 老年癡呆症的幹細胞治療

Stemedica Cell Technologies, Inc.:開發平台分析

  • 各給藥途徑
  • 各分子類型

Stemedica Cell Technologies, Inc.:最近的開發平台趨勢

Stemedica Cell Technologies, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07242CDB

Summary

Global Markets Direct's, 'Stemedica Cell Technologies, Inc. - Product Pipeline Review - 2015', provides an overview of the Stemedica Cell Technologies, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Stemedica Cell Technologies, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Stemedica Cell Technologies, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Stemedica Cell Technologies, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Stemedica Cell Technologies, Inc.'s pipeline products

Reasons to buy

  • Evaluate Stemedica Cell Technologies, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Stemedica Cell Technologies, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Stemedica Cell Technologies, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Stemedica Cell Technologies, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Stemedica Cell Technologies, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Stemedica Cell Technologies, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Stemedica Cell Technologies, Inc. Snapshot
    • Stemedica Cell Technologies, Inc. Overview
    • Key Information
    • Key Facts
  • Stemedica Cell Technologies, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Stemedica Cell Technologies, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Stemedica Cell Technologies, Inc. - Pipeline Products Glance
    • Stemedica Cell Technologies, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Stemedica Cell Technologies, Inc. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
  • Stemedica Cell Technologies, Inc. - Drug Profiles
    • Mesenchymal Stem Cells
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Neural Stem Cells
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Retinal Epithelial Cells
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Stemedica Cell Technologies, Inc. - Pipeline Analysis
    • Stemedica Cell Technologies, Inc. - Pipeline Products by Route of Administration
    • Stemedica Cell Technologies, Inc. - Pipeline Products by Molecule Type
  • Stemedica Cell Technologies, Inc. - Recent Pipeline Updates
  • Stemedica Cell Technologies, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Stemedica Cell Technologies, Inc., Key Information
  • Stemedica Cell Technologies, Inc., Key Facts
  • Stemedica Cell Technologies, Inc. - Pipeline by Indication, 2015
  • Stemedica Cell Technologies, Inc. - Pipeline by Stage of Development, 2015
  • Stemedica Cell Technologies, Inc. - Monotherapy Products in Pipeline, 2015
  • Stemedica Cell Technologies, Inc. - Phase II, 2015
  • Stemedica Cell Technologies, Inc. - Phase I, 2015
  • Stemedica Cell Technologies, Inc. - IND/CTA Filed, 2015
  • Stemedica Cell Technologies, Inc. - Preclinical, 2015
  • Stemedica Cell Technologies, Inc. - Pipeline by Route of Administration, 2015
  • Stemedica Cell Technologies, Inc. - Pipeline by Molecule Type, 2015
  • Stemedica Cell Technologies, Inc. - Recent Pipeline Updates, 2015
  • Stemedica Cell Technologies, Inc., Subsidiaries

List of Figures

  • Stemedica Cell Technologies, Inc. - Pipeline by Top 10 Indication, 2015
  • Stemedica Cell Technologies, Inc. - Pipeline by Stage of Development, 2015
  • Stemedica Cell Technologies, Inc. - Monotherapy Products in Pipeline, 2015
  • Stemedica Cell Technologies, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Stemedica Cell Technologies, Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top